• Nanatinostat Combo Put on FDA’s Fast Track for Hard-to-treat Lymphomas Linked to EBV Infection
  • FDA Grants Fast Track Status to Triumvira’s T-cell Therapy TAC01-CD19 for DLBCL
  • Janssen Requests FDA Approval of Imbruvica-rituximab Combo for First-line Treatment of CLL/SLL
  • Advanced Follicular Lymphoma Patients Show Positive Overall Response to Umbralisib in Phase 2 Trial
  • First Patient Enrolled in Trial Testing Defitelio to Prevent Neurotoxicity in DLBCL Patients Receiving CAR T-cell Therapy
  • Nektar Launches Phase 1 Trial Testing NKTR-255 in Non-Hodgkin’s Lymphoma, Multiple Myeloma
  • Nothing but Mammals: How Cancer Affects Sexual Health
  • Copiktra May Be Treatment Option for Advanced Marginal Zone Lymphoma, Trial Data Show
  • Cirmtuzumab-Imbruvica Combo Trial Opens New Expansion Part for Mantle Cell Lymphoma
  • Copiktra Superior to Arzerra for CLL/SLL Patients with Prior Therapies, Data Suggest
  • Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial
  • Follicular Lymphoma Patients Being Recruited for Phase 2 Trial of Aliqopa-Rituximab Combo